tiprankstipranks
GlycoMimetics (GLYC)
NASDAQ:GLYC

GlycoMimetics Stock Price & Analysis

680 Followers

GLYC Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.51 - $2.50
Previous Close$0.56
Volume107.86K
Average Volume (3M)134.50K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$60.24M
Total Debt (Recent Filing)$1.25M
P/E Ratio-0.5
Beta1.63
Next EarningsNov 10, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-1.20
Shares Outstanding52,423,944
R-Squared0.24
Standard Deviation0.18
10 Day Avg. Volume119,971
30 Day Avg. Volume134,499
P/B Ratio0.53
P/S Ratio163.78
P/CF RatioN/A
P/FCF Ratio-0.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/EbitdaN/A
Price Target Upside2222.26% Upside
Rating ConsensusModerate Buy
Alpha-0.04
Number of Analyst Covering1


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

GLYC FAQ

What was GlycoMimetics’s price range in the past 12 months?
GlycoMimetics lowest stock price was $0.51 and its highest was $2.50 in the past 12 months.
    What is GlycoMimetics’s market cap?
    Currently, no data Available
    When is GlycoMimetics’s upcoming earnings report date?
    GlycoMimetics’s upcoming earnings report date is Nov 10, 2022 which is in 45 days.
      How were GlycoMimetics’s earnings last quarter?
      GlycoMimetics released its earnings results on Aug 03, 2022. The company reported -$0.25 earnings per share for the quarter, beating the consensus estimate of -$0.285 by $0.035.
        Is GlycoMimetics overvalued?
        According to Wall Street analysts GlycoMimetics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does GlycoMimetics pay dividends?
          GlycoMimetics does not currently pay dividends.
          What is GlycoMimetics’s EPS estimate?
          GlycoMimetics’s EPS estimate is -$0.25.
            How many shares outstanding does GlycoMimetics have?
            GlycoMimetics has 52,423,943 shares outstanding.
              What happened to GlycoMimetics’s price movement after its last earnings report?
              GlycoMimetics reported an EPS of -$0.25 in its last earnings report, beating expectations of -$0.285. Following the earnings report the stock price went up 4.478%.
                Which hedge fund is a major shareholder of GlycoMimetics?
                Currently, no hedge funds are holding shares in GLYC

                ---

                GlycoMimetics Stock Analysis

                Smart ScoreNot Ranked
                1
                2
                3
                4
                5
                6
                7
                8
                9
                10
                N/A
                This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
                Learn more about TipRanks Smart Score

                Company Description

                GlycoMimetics

                GlycoMimetics, Inc. operates as a clinical stage biotechnology company, which focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease-related functions of carbohydrates. The company was founded by Rachel K. King and John L. Magnani on April 4, 2003 and is headquartered in Rockville, MD.

                ---
                Similar Stocks
                Company
                Price & Change
                Follow
                AbbVie
                Amgen
                Gilead Sciences
                Moderna
                Vertex Pharmaceuticals

                Popular Stocks

                ---
                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis